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Background: Active smoking is associated with increased thrombosis risk and enhanced efficacy of clopidogrel therapy vs placebo. Prasugrel 
metabolism is not influenced by smoking and has superior pharmacodynamic efficacy, but its relationship to clinical outcomes has not been 
evaluated in medically managed ACS.
methods: 7180 patients <75 y in TRILOGY ACS (prasugrel vs clopidogrel in medically managed ACS) were stratified as active smokers vs ex/
nonsmokers. Event rates by smoking status were evaluated through 30 mos and relationships among smoking and treatment groups and clinical 
outcomes were assessed.
results: 1566 (22%) were active smokers vs 5614 (78%) ex/nonsmokers at randomization. The former were younger, less commonly female and 
diabetic, and more likely to have prior MI, higher creatinine clearance, and prerandomization angiography (Table). At 30 mos, event rates for the 
composite of CVD/MI/stroke in active smokers were 11.7% (prasugrel) vs 20.8% (clopidogrel) with significant interaction between treatment and 
active smoking status for the composite and CVD and MI components. There was no difference in bleeding rates. Significant treatment interactions 
persisted for the composite endpoint (p=0.01) and CVD (p=0.01) after adjusting for baseline differences.
conclusions: There is significant interaction with stronger platelet inhibition with prasugrel vs clopidogrel by smoking status in medically managed 
ACS patients and a significantly enhanced treatment effect with prasugrel. 
Baseline 
characteristics
Not active smoker (n=5614) Active smoker (n=1566) P
Median age, years (IQR) 63.0 (58.0, 69.0) 59.0 (52.0, 64.0) <0.001
Female sex, % 40.3 20.4 <0.001
Diabetes mellitus, % 40.4 32.8 <0.001
Prior MI, % 42.9 47.8 <0.001
Median creatinine clearance, mL/min (IQR) 78.3 (60.4, 99.8) 90.0 (70.2, 114.0) <0.001
Angiography performed, % 39.2 53.6 <0.001
Outcomes by treatment
Unadjusted hazard ratio (95% CI):
prasugrel vs. clopidogrel
Unadjusted hazard ratio (95% CI):
prasugrel vs. clopidogrel
Interaction P
CV death/MI/stroke 1.06 (0.90-1.25) 0.54 (0.39-0.74) 0.0002
CV death 1.12 (0.88-1.43) 0.48 (0.30-0.77) 0.0018
MI 0.98 (0.80-1.21) 0.62 (0.42-0.91) 0.0403
